TradeFlare's AI research teams analysed CABA on 5 market nights between May 11, 2026 and September 8, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 8, 2026 | BUY | $3.47 | $4.16 / $2.95 | -20.6% | -38.2% | The post-earnings drift signal suggests a short-to-medium term opportunity. |
| September 7, 2026 | BUY | $3.47 | $4.16 / $2.60 | -20.6% | -38.2% | The PEAD signal suggests a short-term upward drift, and the bullish fundamental and sentiment teams support a medium-term outlook. |
| June 5, 2026 | BUY | $3.51 | — / — | -7.4% | -4.6% | Positive clinical trial updates for autoimmune disease therapies. |
| May 12, 2026 | BUY | $3.82 | — / — | -9.9% | -16.2% | Continued positive clinical trial data readouts. |
| May 11, 2026 | HOLD | $3.88 | $5.00 / $3.29 | -13.9% | -15.7% | The PEAD signal suggests short-term momentum, but the market regime and risk profile necessitate caution. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.